Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5288124 | 1.00 | KDM4E (0.57) | KDM4ENPC1RAB9AHRH3HPGD | |
| SCHEMBL5287827 | 1.00 | KDM4E (0.57) | KDM4ENPC1RAB9AHRH3HPGD | |
| SCHEMBL1472922 | 0.89 | KDM4E (0.52) | KDM4ENPC1RAB9AHRH3HPGD | |
| SCHEMBL5294746 | 0.84 | KDM4E (0.51) | KDM4ENPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL8283237 | 0.81 | KDM4E (0.58) | KDM4ENPC1RAB9AMAPTL3MBTL1 | |
| SCHEMBL5289807 | 0.80 | HRH3 (0.51) | HRH3HPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL5295906 | 0.80 | HRH3 (0.51) | HRH3HPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL1474034 | 0.80 | HRH3 (0.51) | HRH3HPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL27669293 | 0.79 | EDNRA (0.54) | KDM4ENPC1RAB9AHRH3 | |
| SCHEMBL1473531 | 0.75 | KDM4E (0.47) | KDM4ENPC1RAB9AHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112089-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2011-05-12 | — | — | US | disclosed |
| US-20110112089-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2011-05-12 | — | — | US | disclosed |
| US-20110112089-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2011-05-12 | — | — | US | disclosed |
| US-7915300-B2 | Especially those of papain superfamily; prophylaxis or treatment of disorders stemming from misbalance of physiological proteases such as cathepsin K; (3aS,6S,6aS)-6-Fluoro-4-{(S)-4-methyl-2-[(R)-2,2,2-trifluoro-1-(4'-methanesulfonylbiphenyl-4-yl)-ethylamino]-pentanoyl}-tetrahydro-furo[3,2-b]pyrrol-3-one | MEDIVIR AB (SE) | 2011-03-29 | — | — | US | disclosed |
| US-7915300-B2 | Especially those of papain superfamily; prophylaxis or treatment of disorders stemming from misbalance of physiological proteases such as cathepsin K; (3aS,6S,6aS)-6-Fluoro-4-{(S)-4-methyl-2-[(R)-2,2,2-trifluoro-1-(4'-methanesulfonylbiphenyl-4-yl)-ethylamino]-pentanoyl}-tetrahydro-furo[3,2-b]pyrrol-3-one | MEDIVIR AB (SE) | 2011-03-29 | — | — | US | disclosed |
| US-7915300-B2 | Especially those of papain superfamily; prophylaxis or treatment of disorders stemming from misbalance of physiological proteases such as cathepsin K; (3aS,6S,6aS)-6-Fluoro-4-{(S)-4-methyl-2-[(R)-2,2,2-trifluoro-1-(4'-methanesulfonylbiphenyl-4-yl)-ethylamino]-pentanoyl}-tetrahydro-furo[3,2-b]pyrrol-3-one | MEDIVIR AB (SE) | 2011-03-29 | — | — | US | disclosed |
| CN-100469780-C | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2009-03-18 | — | — | CN | disclosed |
| US-20080234260-A1 | Cysteine Protease inhibitors | MEDIVIR AB (SE) | 2008-09-25 | — | — | US | disclosed |
| US-20080234260-A1 | Cysteine Protease inhibitors | MEDIVIR AB (SE) | 2008-09-25 | — | — | US | disclosed |
| US-20080234260-A1 | Cysteine Protease inhibitors | MEDIVIR AB (SE) | 2008-09-25 | — | — | US | disclosed |
| WO-2005066180-A9 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2008-09-25 | — | — | WO | disclosed |
| CN-1918169-A | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2007-02-21 | — | — | CN | disclosed |
| WO-2007006714-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006715-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| EP-1701960-A1 | CYSTEINE PROTEASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005066180-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234260-A1 | Cysteine Protease inhibitors | CTSS, CTSZ, CTSK | KDM4E 2541/4885NPC1 482/4885RAB9A 1155/4885 |
| US-20110112089-A1 | Cysteine Protease Inhibitors | CTSS, CTSZ, CTSK | KDM4E 2528/4885NPC1 438/4885RAB9A 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.